HALO: Drug delivery royalties, PEG 0.21

Pass #12 in this channel's daily small-cap screen. Halozyme Therapeutics (NASDAQ: HALO) clears all four hard filters and trades at one of the lowest PEG ratios of any profitable biotech platform in the US market — not because the business is deteriorating, but because investors are pricing a single event: a 2027 patent expiry.

Current price: $71.60 (June 4, 2026 close). Market cap: $8.49B. 1

Four-filter verification

Hard screening metrics — HALO (TTM through Q1 2026)

All four filters passed as of June 5, 2026

Market cap

$0.00−15.1%vs $10B cap

TTM revenue growth

0.0+9.1%above 30% floor

PEG ratio

0−79.0%vs 1.0 ceiling

TTM operating cash flow

$0.00+34.5%YoY growth

Loading stats card…

A note on the PEG: StockAnalysis calculates it as Forward P/E 8.12 divided by the 3-year EPS growth forecast of 39.29%, yielding 0.207. Finviz reports PEG of 0.18, reflecting a slightly lower Forward P/E input (~7.21). Both calculations land well under the 1.0 ceiling, from independent platforms with transparent methodology. 1 2 3 4

What Halozyme does

Halozyme's core product is not a drug — it is a delivery mechanism. The ENHANZE platform uses a proprietary enzyme called rHuPH20 (recombinant human hyaluronidase PH20) to temporarily break down hyaluronan in subcutaneous tissue, allowing biologics that would otherwise require intravenous infusion to be injected under the skin in minutes rather than hours. 5

Patients benefit from shorter treatment sessions and the possibility of home administration. Partner drug companies benefit from differentiated products, extended patent protection on reformulated biologics, and improved patient adherence. Halozyme benefits from royalties on every vial sold — without manufacturing the drugs themselves.

That asset-light royalty structure is the key to the financial profile. HALO does not carry inventory, does not run clinical trials for its own pipeline drugs, and does not bear the binary approval risk that weighs on traditional biotechs. It licenses ENHANZE, collects milestones during development, and then receives mid-single-digit to low-double-digit royalty rates on net sales once a product launches.

Ten ENHANZE-enabled products are now commercialized across more than 100 global markets, reaching over 1 million patients. 5 Three of these drive most of the royalty revenue: DARZALEX SC (Janssen's subcutaneous multiple myeloma drug), Phesgo (Roche's SC breast cancer combination), and VYVGART Hytrulo (argenx's SC autoimmune therapy). Together, these three blockbusters generated $868 million in royalty revenue in 2025, up 52% year-over-year. 6

In November and December 2025, Halozyme made two acquisitions that extend the platform beyond ENHANZE: Elektrofi (now Halozyme Hypercon, Inc.) adds microparticle hyperconcentration technology, and Surf Bio adds polymer-based drug concentration technology. These represent the second and third delivery platform legs that management is now licensing independently.

Revenue trend and the EPS mystery

Eight quarters of HALO's top-line data show a business accelerating, not plateauing.

Loading chart…

Q1 2026 revenue was $376.7 million, up 42.2% year-over-year — accelerating from the 18-19% YoY rates in mid-2025. TTM revenue is $1.51 billion. 2 5

Why did GAAP EPS decline? A surface read of HALO's income statement shows TTM revenue +39.12% alongside GAAP net income -28.13% — a contradiction that explains much of the current discount. The full explanation is a single line item: a $284.9 million acquired in-process R&D (IPR&D) charge triggered by the Surf Bio acquisition in Q4 2025. This is a non-cash accounting write-off required under GAAP when a company acquires technology that has not yet received regulatory approval. It does not represent cash spent in Q4 2025 and does not recur. 6

The impact was severe enough to swing Q4 2025 alone to a GAAP net loss of $141.6 million. Strip out that charge and the underlying picture is different:

Metric	FY2024	FY2025	Change
GAAP diluted EPS	$3.43	$2.56	-25.4%
Non-GAAP diluted EPS	$4.23	$4.15	-1.9%
Revenue	$1.10B	$1.51B	+37.6%
Operating cash flow	$503.9M	$677.4M	+34.4%

The normalization is already showing. 7 6 Q1 2026 GAAP diluted EPS was $1.22, up 31% year-over-year versus $0.93 in Q1 2025. Non-GAAP diluted EPS was $1.60, up 44% year-over-year. 5

Valuation versus peers

Among drug delivery platform and royalty-model biotechs, HALO's forward multiple stands apart. The chart below plots Forward P/E for each peer — HALO's 8.12x is less than a fifth of the peer median.

Loading chart…

The full multi-metric comparison 4 8 9 10 11 12:

Company	Market cap	Fwd P/E	PEG	EV/EBITDA	P/FCF	Gross margin
HALO (Halozyme)	$8.49B	8.12	0.21	10.86	12.72	82.8%
LGND (Ligand Pharmaceuticals)	$4.73B	44.53	2.47	32.73	38.43	83.2%
UTHR (United Therapeutics)	$23.25B	19.22	1.98	12.77	22.86	86.6%
TECH (Bio-Techne)	$8.33B	26.53	3.72	22.95	30.88	66.4%
RGEN (Repligen)	$7.14B	60.14	2.99	52.46	67.32	53.1%
AVTR (Avantor)	$6.50B	11.70	10.33	10.59	14.81	32.1%

HALO's gross margin of 82.8% matches LGND and exceeds every other peer. Its FCF margin is 44.3% — the business itself is not structurally impaired. The discount is entirely forward-looking: the market is applying a deep haircut to earnings beyond the 2027 patent expiry and has not yet credited the Hypercon platform or contractual royalty step-downs.

One metric that appears extreme but is technically misleading: HALO's price-to-book ratio of 38.6x and reported ROE of 99.4%. These reflect a book equity base of only $219.6 million, itself the result of accumulated goodwill write-offs and aggressive debt-financed buybacks. The book value figures carry no analytical weight here. 4

Balance sheet and debt structure

Total debt is $2.145 billion as of March 31, 2026. That sounds large for an $8.5B market cap company, but the structure and cost matter more than the headline number. Four metrics tell the real story:

Balance sheet snapshot — HALO (March 31, 2026)

Debt is near-zero coupon; FCF covers the convert stack within 3 years

Total debt

$0.00

Net debt

$0.00+1.9%Net Debt / EBITDA

TTM free cash flow

$0.00+44.3%FCF margin

Interest coverage

0+100.0%near-zero coupon debt

Loading stats card…

The debt consists of two tranches of convertible senior notes issued in November 2025: $750 million at 0% interest (due February 15, 2031) and $750 million at 0.875% interest (due November 15, 2032), both with a conversion price of $87.20 per share — approximately 22% above the current stock price. 13 3 4 14 The proceeds from the offering retired approximately $1.02 billion of prior 2027/2028 converts, extending the maturity wall by four to five years.

Cash and equivalents stood at $318.6 million as of March 31, 2026, yielding net debt of $1.826 billion. Net Debt/EBITDA is 1.92x. 13 The interest coverage ratio is 44.97x — annual interest expense on $1.5 billion in near-zero coupon converts is negligible. 4

The critical question is the 2031/2032 maturity. If HALO stock remains below $87.20 at maturity, the company must repay $1.5 billion in cash. At $667.65 million in TTM free cash flow and a $750 million revolving credit facility available, the company generates enough annual FCF to retire the full convert stack within two to three years. This is a manageable obligation, not a solvency risk. 3

Growth catalysts

Five new partnership agreements signed in the six months before Q1 2026 earnings make this one of HALO's most active partnership windows in its history.

GSK (May 7, 2026): Global ENHANZE collaboration across multiple oncology targets — the first time ENHANZE is being applied to antibody-drug conjugates (ADCs), one of the fastest-growing areas in oncology. GSK pays upfront fees, milestones, and royalties. First clinical trial is projected to initiate in 2026. 5

Oruka Therapeutics (May 6, 2026): Global exclusive Hypercon license for ORKA-001 (an IL-23p19 inhibitor targeting psoriatic disease) plus one additional target option. Oruka pays upfront, milestones, and mid-single-digit royalties. This is the first Hypercon deal in autoimmune disease. 5

Vertex Pharmaceuticals (April 7, 2026): Global exclusive Hypercon collaboration for up to three targets, with $15 million upfront plus milestones and royalties. Vertex is one of the most credentialed biotechs in the industry — its participation validates the Hypercon platform for serious chronic disease. 5

Takeda (January 2026): ENHANZE for vedolizumab (ENTYVIO), an existing blockbuster IBD drug by Takeda, enabling a subcutaneous formulation for Crohn's disease and ulcerative colitis. Phase 2/3 data for TAK-881 (20% immunoglobulin) in primary immunodeficiency are positive — this could become the 11th commercialized ENHANZE product. 5

Merus (November 2025): ENHANZE for petosemtamab, a bispecific antibody targeting EGFR and LGR5 for head and neck cancer. 5

Across the Hypercon platform specifically, Halozyme has now signed five agreements covering 17 potential drug targets. First approvals are projected in the 2030/2031 timeframe. CEO Dr. Helen Torley described the strategic significance directly: "This momentum creates durable new royalty opportunity beginning in the 2030s and extending to at least the mid-2040s." 5

2026 financial guidance (reiterated May 11, 2026): total revenue $1.710–$1.810 billion (22–30% YoY growth), royalty revenue $1.130–$1.170 billion (30–35% growth, the first year to exceed $1 billion), adjusted EBITDA $1.125–$1.205 billion (71–83% growth), and non-GAAP diluted EPS of $7.75–$8.25 (87–99% YoY growth). 5 At the $8.00 midpoint, the Forward Non-GAAP P/E is approximately 8.9x.

A new $1 billion share repurchase program (through December 2028) was announced alongside Q1 earnings, with at least $400 million projected for 2026. HALO had already repurchased $190.6 million in Q1 2026 alone, and previously bought back $342.4 million in shares during FY2025. 3 Guidance does not include the impact of future repurchases — actual per-share EPS will be higher as shares retire.

Key risks

Patent cliff (HIGH risk). The core ENHANZE rHuPH20 US patent expires September 23, 2027 (benefiting from a patent term extension from the original March 2024 date). The European counterpart expires March 6, 2029. 15 Management's rebuttal rests on three layers: (1) existing partner contracts include royalties at reduced "step-down" rates post-expiry, not zero; (2) product-specific formulation patents on each partnered drug extend protection beyond the platform patent; (3) Hypercon and Surf Bio carry entirely separate IP portfolios unaffected by the rHuPH20 expiry. The bear case — articulated by analyst Stephen Ayers in a July 2025 Seeking Alpha downgrade — argues that buybacks over R&D investment and unclear post-ENHANZE strategy create a value trap risk. Neither position is demonstrably wrong yet; the royalty step-down magnitude after 2027 is the key unresolved variable, and neither management nor public filings have disclosed a specific numerical estimate.

Insider selling (MEDIUM risk). CEO Helen Torley has sold shares in 37 separate transactions over the past 18 months, totaling approximately 626,569 shares ($16.95 million) with zero purchases. 16 Her most recent sales were 50,000 shares on June 1, 2026, at prices between $65.84 and $66.83. Insider ownership stands at 1.03% — low by the standard of founder-led growth companies. Consistent, large selling by a sitting CEO is a signal worth tracking; it does not prove the bear thesis but indicates limited personal alignment at current prices.

Short interest (MEDIUM-HIGH risk). As of the most recent data, 13.39 million shares are short — 11.29% of the float, with 7.89 days to cover. 4 Short interest declined from 14.38 million shares in the prior period, suggesting some shorts have been covering. Elevated short interest of this magnitude in a profitable, cash-generative business typically reflects a concentrated narrative bet (the patent cliff), not broad fundamental deterioration. A positive catalyst — an earlier-than-expected Hypercon deal, a strong Q2 earnings print, or a royalty step-down disclosure that proves less severe than feared — could accelerate the covering.

Partnership concentration risk (HIGH risk — unquantified). Three partners — Janssen (DARZALEX SC), Roche (Phesgo), and argenx (VYVGART Hytrulo) — likely account for a disproportionate share of the $868 million in 2025 royalty revenue. Halozyme has not disclosed individual partner revenue contributions, and the specific concentration figures were not available from public filings in this analysis. If any single partner were to terminate an agreement, reformulate without ENHANZE, or face a material drug safety issue, the revenue impact could be severe and rapid.

Debt maturity wall (LOW-MEDIUM risk). $1.5 billion in convertible notes matures in 2031 and 2032. If the stock price stays below the $87.20 conversion price — currently 22% above market — at those maturities, HALO repays in cash. At $667 million in annual FCF and a $750 million revolving credit facility, the company has the capacity. The risk is not insolvency; it is the opportunity cost of directing $1.5 billion in FCF toward debt repayment rather than buybacks, new acquisitions, or technology licensing. 14

Competitive technology threat (MEDIUM risk). Alteogen, a South Korean biotech, has partnered with Merck to enable a subcutaneous formulation of Keytruda (pembrolizumab) using ALT-004, a competing hyaluronidase. Halozyme secured a preliminary injunction in German courts blocking distribution of Keytruda SC, but the broader patent litigation outcome across markets is unresolved. If ALT-004 gains meaningful market share in key oncology indications without licensing ENHANZE, it represents a structural competitive threat to HALO's platform exclusivity.

Price action, analyst consensus, and upcoming catalysts

HALO has traded roughly flat year-to-date, moving from approximately $69.82 at year-end 2025 to $71.60 on June 4, 2026 — a 2.5% gain against a period that included a sharp intraday decline after Q1 earnings (before recovering). 1 The 52-week range is $51.06–$82.22. Beta is 0.87, relatively low for a biotech platform. Average daily volume is approximately 2.07 million shares.

Twelve analysts cover HALO. The consensus is Moderate Buy: 7 Buy ratings, 4 Hold, 1 Sell. 1 The average price target runs between $81.60 and $83.90, implying 17–18% upside from the current price. Analyst targets carry a systematic upward bias and should be read as directional indicators, not precise forecasts.

Among the more specific calls: Morgan Stanley (Overweight, target $93) described Q1 results as "solid" and reiterated its rating after the earnings release. H.C. Wainwright analyst Mitchell Kapoor raised his target to $95 from $90 (Buy rating), citing the Q1 royalty reset and the five new partnership agreements as underappreciated by the market.

Three specific catalysts to watch:

Q2 2026 earnings (estimated August 2026): The thesis test is whether royalty revenue continues to accelerate toward the $1.13–$1.17 billion full-year guidance and whether Non-GAAP EPS tracks toward the $7.75–$8.25 range. Q1 $1.60 Non-GAAP EPS annualizes to $6.40, so the second half needs to deliver a meaningful step-up.
New ENHANZE or Hypercon partnership announcements: Management set a goal of at least three new SC delivery platform agreements in 2026. Three were already signed in Q1 (Vertex, Oruka, GSK). Any additional deal would signal demand above guidance — and Hypercon deals in particular push royalty visibility well past the 2027 ENHANZE patent expiry.
Patent litigation outcome in Keytruda SC case: A ruling that expands or upholds Halozyme's injunction against Alteogen/Merck would remove a specific competitive risk. An adverse ruling would validate the bear case on platform exclusivity.

Bottom line

HALO passes all four hard filters with clear margins: TTM revenue growth +39.1% (vs. 30% floor), PEG 0.21 (vs. 1.0 ceiling), TTM OCF $677.4 million, and an $8.49B market cap well inside the $10B cap. 1 2 3

The bull thesis is a valuation argument: the market is pricing near-total post-2027 royalty impairment. That requires believing that contractual step-down royalties, product-level formulation patents, and five Hypercon deals (with potential for more) collectively generate almost nothing after 2029. That is a high bar for the bear case to clear.

The bear thesis is a durability argument: ENHANZE is approaching expiry, the CEO is selling stock consistently, 11% of the float is short, and management has not disclosed a specific numerical estimate of the royalty step-down. Those are real uncertainties — not dismissible.

Investors with a view on the royalty durability question have a specific thesis to evaluate. Those who conclude the Hypercon and contractual royalty protections are credible get a profitable, asset-light platform at 8x forward earnings and a PEG of 0.21. Those who conclude the patent cliff is terminal have a reason to pass.

Two concrete verification triggers: the Q2 2026 earnings call should provide an updated read on full-year royalty trajectory, and any disclosure of partner revenue concentration in the upcoming 10-K would quantify the single largest unresolved risk.

This is pass #12 in the channel's daily screen. Previous picks have covered specialty pharma (ANIP), marketing data (ZETA), education/healthcare payments (FLYW), neobanking (DAVE), specialty insurance (ASIC), mortgage tech (FIGR), bill payments (PAY), marketing SaaS (KVYO), semiconductors (MXL), consumer lending (TREE), and emerging-market payments (DLO).

Cover image: AI-generated editorial card.